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port-wine stains through greater vessel heating 
and deeper vascular injury.2 The improved tech-
nology targets the heterogeneity in blood-vessel 
sizes that is characteristic of port-wine stains.3
Any study evaluating the response of port-wine 
stains to treatment should include an analysis 
based on the location of the anatomical malfor-
mation and the patient’s age. As compared with 
other areas of the face and neck, port-wine stains 
on the center of the face have been shown to re-
spond less effectively to treatment and are more 
likely to recur.4 An aggressive approach to treat-
ing infants and young children can also allow for 
more rapid and complete clearing.5
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The Authors Reply: With ongoing research in 
medicine, investigating the 10-year follow-up re-
sults of any medical treatment inevitably leads to 
somewhat outdated results at the time of presen-
tation. This is especially the case in a field that is 
subject to continuous development, such as pulsed-
dye–laser treatment of port-wine stains. As Nelson 
and Geronemus point out, the results with newer 
pulsed-dye lasers have been reported to be prom-
ising and superior to the results with the laser 
used in our study. However, to date no controlled 
comparative studies have shown improved clinical 
efficacy. Whether the new lasers have improved 
long-term efficacy remains to be reported; in 
light of our observation of the recurrence of port-
wine stains, we certainly hope they do.
No differences or trends in responses to treat-
ment related to the anatomical locations of the 
port-wine stains were observed in either the origi-
nal study1,2 or the current follow-up study, possi-
bly because of the relatively small number of pa-
tients. Furthermore, in the original study, age was 
shown to have no influence on the response to 
treatment. Therefore, we refrained from perform-
ing age-dependent analyses in the current long-
term follow-up assessment.
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Treatment of Kawasaki Disease
To the Editor: In their trial of pulsed cortico-
steroid therapy for primary treatment of Kawa-
saki disease, Newburger et al. (Feb. 15 issue)1 
report that, as compared with placebo, a single 
pulsed dose of corticosteroid resulted in a shorter 
initial period of hospitalization but that the total 
numbers of days of fever and hospitalization, the 
rates of retreatment, and the coronary-artery out-
comes did not differ significantly between the two 
groups. The use of a single-dose regimen without 
tapering most likely contributed to their results. 
A single application of a corticosteroid, even at a 
high dose, may have a strong but only short-lived 
effect, which could therefore be associated with 
a secondary increase in inflammation.
On the basis of nearly 10 years of clinical 
experience,2 we designed a regimen involving a 
short intravenous course of prednisolone and 
subsequent oral administration of prednisolone 
followed by tapering.3 In a randomized trial per-
formed to test the effectiveness of the regimen 
as an adjunct to intravenous immune globulin, 
the incidences of retreatment and coronary-artery 
abnormalities within 1 month after the start of 
treatment were less frequent in the corticosteroid 
group than in the group receiving immune globu-
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lin alone. Our regimen therefore appears to be 
more efficacious than the control regimen. Never-
theless, the optimal corticosteroid regimen re-
mains an issue in the primary therapy of Kawa-
saki disease.
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To the Editor: Newburger et al. studied the ef-
fects of adding intravenous methylprednisolone to 
conventional therapy for Kawasaki disease. The 
authors found a significantly lower frequency of 
coronary-artery abnormalities in the intravenous-
methylprednisolone group than in the placebo 
group within the subgroup of patients who re-
quired retreatment with intravenous immune 
globulin.
The identification of predictors of coronary ab-
normalities in Kawasaki disease is still problem-
atic. Failure of initial treatment with intravenous 
immune globulin remains the most consistent 
risk factor for cardiac abnormalities.1 Adminis-
tration of intravenous methylprednisolone after 
the failure of initial treatment with intravenous 
immune globulin does not seem to be effective in 
reducing the risk of coronary damage,2 although 
the current data suggest that this might not be the 
case for patients who do not have a response to 
intravenous immune globulin and who have pre-
viously received intravenous methylprednisolone.
Since intravenous methylprednisolone admin-
istered as a single dose appears to be safe,3 and 
given our inability to identify a priori the patients 
who will not have a response to intravenous im-
mune globulin, it seems obvious that the concur-
rent use of a single dose of intravenous methyl-
prednisolone and intravenous immune globulin 
may be our best choice at the moment. It is un-
realistic to expect that trials powered to show 
the effectiveness of intravenous methylpredniso-
lone could be accomplished anytime soon.
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To the Editor: Although the study by Newburger 
et al. involved assessment of coronary-artery out-
comes with the use of transthoracic echocardi-
ography, we were quite surprised by the inclusion 
of an example of a coronary aneurysm seen on 
multidetector computed tomography (CT) in the 
accompanying Perspective article by Burns.1
We and others2,3 have shown the efficacy of 
noninvasive magnetic resonance imaging (MRI) 
of the heart for both the identification and char-
acterization of coronary artery disease in patients 
with Kawasaki disease (Fig. 1). Patients with 
Kawasaki disease require frequent observation 
over many decades. Given the relatively high doses 
of ionizing radiation associated with multidetector 
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Figure 1. Three-Dimensional Steady-State Free-Precession 
MRI of the Whole Heart in an 8-Year-Old Boy with 
 Kawasaki Disease and Serial Aneurysms (A) in the 
Right Coronary Artery.
No contrast material was administered.
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CT 4 and the heightened potential for radiation-
induced fatal cancer in children,5 we believe that, 
if transthoracic echocardiography is inadequate, 
these younger patients are best served by the use 
of coronary MRI.
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The Authors Reply: Inoue and colleagues de-
scribe the results of their open trial using a pro-
longed course of corticosteroids, which we discuss 
in our article. We found that clinically significant 
coronary-artery abnormalities were infrequent in 
patients in both of our study groups. For this 
reason, although the optimal corticosteroid regi-
men may be unknown, we believe that cortico-
steroid regimens requiring a prolonged course of 
treatment would be difficult to rationalize for the 
primary treatment of all patients with Kawasaki 
disease.
Taddio and Rosé highlight an important ques-
tion arising from our analyses. Our study was de-
signed to test the hypothesis that the addition of 
intravenous methylprednisolone to conventional 
primary treatment of Kawasaki disease would im-
prove coronary-artery outcomes; the study groups 
had similar overall coronary outcomes. A post hoc 
subgroup analysis suggested that primary cortico-
steroid therapy reduced the incidence of coronary-
artery abnormalities in a high-risk subgroup of 
patients in our study who required retreatment 
with intravenous immune globulin because of 
persistent or recrudescent fever. However, such 
subgroup analyses must be interpreted with cau-
tion1; the literature is replete with subgroup 
analyses suggesting differential responses to 
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therapy, findings that have been shown to be er-
roneous in subsequent prospective trials.2 Chil-
dren with Kawasaki disease can be characterized 
at the time of presentation with respect to their 
risk of resistance to intravenous immune globu-
lin.3 Until further studies are conducted in high-
risk patients, we do not believe that corticosteroid 
therapy should be used in the primary treatment 
of Kawasaki disease.
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Dr. Burns Replies: Imaging of the coronary ar-
teries is important in the long-term management 
of aneurysms in patients with Kawasaki disease. 
Transthoracic echocardiography can be used only 
to image the proximal arteries, is dependent on a 
high level of technical skill, and cannot reliably 
detect stenosis. Advantages of multidetector CT 
are the assessment of calcification and soft plaque, 
rapid collection of data, and straightforward in-
terpretation of images. With proper gating to the 
cardiac cycle and lowering of the heart rate with 
beta-adrenergic blockade, exposures of approxi-
mately 0.67 mSv have been documented for coro-
nary-artery studies of children involving multi-
detector CT (Larkin G, GE Healthcare: personal 
communication) (for comparison, one chest radio-
graph results in exposure to 0.02 mSv). MRI is safe, 
but many centers cannot image the coronary ar-
teries with sufficient precision. All these ap-
proaches require general anesthesia for young 
patients, and MRI requires a longer time to cap-
ture images than does multidetector CT and thus 
increases the time under anesthesia and associat-
ed risks. Clearly, this is an area of medicine that 
is in flux. We look forward to the time when safe, 
noninvasive imaging methods are widely avail-
able at all centers for these children.
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